Amna Ramzan, MD
Neurology · Houston, TXNPI 1063953297
Payments from drug & device makers
Across 203 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$674
- UCB, Inc.$549
- Eisai Inc.$431
- Novartis$419
- Takeda Pharmaceuticals U.S.A., Inc.$314
- AstraZeneca$190
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$2005%
- Food & beverage$4,10595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $674 |
| UCB, Inc. | 15 | $549 |
| Eisai Inc. | 17 | $431 |
| Novartis | 23 | $419 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $314 |
| AstraZeneca(2 entities) | 8 | $190 |
| Grifols USA, LLC | 7 | $160 |
| Lilly USA, LLC | 9 | $159 |
| CSL Behring | 8 | $157 |
| Pfizer | 7 | $153 |
| Acadia Pharmaceuticals Inc | 8 | $125 |
| Calliditas Therapeutics US Inc. | 1 | $121 |
| Neurocrine Biosciences, Inc. | 4 | $111 |
| Jazz Pharmaceuticals Inc. | 4 | $110 |
| SK Life Science, Inc. | 4 | $103 |
| Argenx US, Inc. | 5 | $100 |
| Genentech USA, Inc. | 3 | $54 |
| Averitas Pharma Inc. | 2 | $51 |
| Merz Pharmaceuticals, LLC | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Corium, LLC | 1 | $30 |
| Biogen | 2 | $30 |
| TG Therapeutics, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $21 |
| Abbott | 1 | $20 |
| Sanofi | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,305 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 37 | $57,992 |
| Galantamine Hbr | 114 | $7,876 |
| Gabapentin | 232 | $2,086 |
| Pyridostigmine Bromide | 36 | $1,575 |
| Mycophenolate Mofetil | 22 | $1,539 |
| Levetiracetam | 65 | $1,479 |
| Duloxetine Hcl | 76 | $1,315 |
| Lacosamide | 11 | $1,008 |
| Memantine Hcl | 56 | $987 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 51 | $983 |
| Pregabalin | 61 | $776 |
| Cyclobenzaprine Hcl | 117 | $761 |
| Atorvastatin Calcium | 62 | $648 |
| Donepezil Hcl | 75 | $642 |
| Sertraline Hcl | 76 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $674 | $57,99237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.